NCATS Strategic Planning Dorit Zuk, Ph.D. Director, OPCS A NCATS - - PowerPoint PPT Presentation

NCATS Strategic Planning

Dorit Zuk, Ph.D. Director, OPCS A NCATS Council/ CAN Review Board Meeting S eptember 3rd, 2015

2

3

Strategic Planning Process Timeline

S mall group discussions with staff

Dec 2014-Apr 2015

Focus groups develop RFI topics

Aug 2015

Publish RFI and S trategic Plan website

End-Sep 2015

Conduct Town Hall webinars

Oct-Nov 2015

Analyze stakeholder feedback

Dec 2015-Jan 2016

Update Council/ CAN RB

Jan 2016

Draft, review and publish S trategic Plan

Spring 2016

Stage 1 – Internal NCATS Discussion

• S

mall group discussions with all NCATS staff about NCATS ’ vision and foundational strategy

• Dec 2014-April 2015: 27 meetings, 252 staff
• Feedback analysis underway
• Will inform the development of the

strategic plan

5

Stage 2 – Gathering Feedback from External Stakeholders

• S

takeholders include among others:

• Patients and members of the health advocacy

community

• Basic, translational and clinical scientists at universities

and research institutions

• Biotechnology and pharmaceutical industry members
• NIH colleagues
• Other government agencies (e.g., FDA, EP

A, DoD)

• Policy-makers and funders
• As well as the general public
• August - calls with NCATS

staff and Council/ CAN RB members to develop the key strategic planning topics

6

Proposed Thematic Areas

• Improving t he Drug Development Process
• Pre-Clinical Innovat ion: Test ing & Predict ive Models
• Repurposing Drugs
• Re-Engineering t he Clinical & Translat ional Process
• Accelerat ing & S

upport ing Rare Diseases Research

• Part nerships wit h S

t akeholder Groups

Obviously - overlap among t he areas. Feedback will be int egrat ed.

Cont inuing t he discussion t oday…

7

Improving the Drug Development Process

S

• me possible RFI topics raised on call:
• Import ance of int er-operabilit y of bioinformat ic

systems

• Int egrat ing pat ient dat a int o pre-clinical research
• Focus on t he precompet it ive space
• Expanding t herapeut ic modalit ies

8

Pre-Clinical Innovation: Testing & Predictive Models

• S
• me possible RFI topics raised on call:
• Approximat ing t he human condit ion
• Range of dat a needed for robust models
• Innovat ive mechanisms for dat a collect ion and

analysis

• Engaging pat ient communit y in st udy design

9

Re-Engineering the Clinical & Translational Process

• S
• me possible RFI topics raised on call:
• Connect ing research and researchers along t he

t ranslat ional science spect rum (“ de-siloizing” )

• Measuring innovat ion in t ranslat ion
• S

killset s and core compet encies needed in t ranslat ional science

• Defining and developing clinical informat ics

10

Repurposing Drugs

• S
• me possible RFI topics raised on call:
• S

yst emat ic approaches

• Innovat ive part nerships t o facilit at e repurposing
• Involving t he communit y in repurposing effort s

11

Accelerating & Supporting Rare Diseases Research

S

• me possible RFI topics raised on call:
• Examinat ion of commonalit ies
• Defining rare diseases in an ‘ omics era
• Engagement of new part ners
• Pat ient -driven research

12

Partnerships with Stakeholder Groups

S

• me possible RFI topics raised on call:
• Engaging wit h t he pat ient communit y: a bi-

direct ional process

• Nat ure of t he “ on-ramp”
• Innovat ive part nership models
• Modern communicat ion and educat ional t ools

13

Other Thematic Areas?

14

What we need next from Council/CAN RB

• Please send any additional comments on key

topics/ questions for stakeholder engagement in the next 10 days

• When released, publicize and encourage your

networks to respond to RFI and to participate in subsequent Town Hall webinars

• Provide your own feedback

15

“It’s a Team Sport”

NCATS S trategic Planning Team

Penny Burgoon Taylor Gilliland Christine Cutillo Cindy McConnell Megan Cowles

16

• 250+ NCATS

staff who participated in small group discussions

• Council and CAN Review Board members